CTLA4 and lung cancer: JTX2011/vopratelimab is also being investigated in a phase I/II study of solid tumors in combination with either anti‐PD‐1 or anti‐CTLA‐4 therapy (NCT04319224) and in combination anti‐CTLA‐4 therapy in a phase 2 study of non‐small cell lung cancer and urothelial cancers (NCT03989362).